dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Makrantonakis, P. | en |
dc.contributor.author | Tsavaris, N. | en |
dc.contributor.author | Kalogera-Fountzila, Anna | en |
dc.contributor.author | Giannakakis, T. | en |
dc.contributor.author | Beer, M. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Makrantonakis, P. | en |
dc.creator | Tsavaris, N. | en |
dc.creator | Kalogera-Fountzila, Anna | en |
dc.creator | Giannakakis, T. | en |
dc.creator | Beer, M. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.date.accessioned | 2018-06-22T09:53:08Z | |
dc.date.available | 2018-06-22T09:53:08Z | |
dc.date.issued | 1991 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41673 | |
dc.description.abstract | Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the median weekly dose 78% of the protocol requirement. Forty-eight patients were evaluable for response; 3 achieved a complete remission which lasted for 17, 24 and 65 weeks, respectively, and 14 a partial remission. Median survival was 32 weeks. Toxicity included nausea/vomiting (68%), anemia (24%), leukopenia (37%), thrombocytopenia (8%), alopecia (81%), stomatitis (24%), diarrhea (14%), fever (19%) and fatigue (14%). Also 1 treatment-related death occurred and 2 cases of arrhythmia. Monotherapy with high doses of epirubicin has definite activity in advanced breast cancer and deserves further study in combination with hematopoietic growth factors which might allow a higher dose intensity. | en |
dc.language.iso | eng | en |
dc.source | Tumori | en |
dc.subject | Adult | en |
dc.subject | Female | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Breast neoplasms | en |
dc.subject | Middle aged | en |
dc.subject | Drug administration schedule | en |
dc.subject | Drug evaluation | en |
dc.subject | Epirubicin | en |
dc.subject | Remission induction | en |
dc.title | High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 77 | |
dc.description.issue | 3 | |
dc.description.startingpage | 232 | |
dc.description.endingpage | 236 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Kalogera-Fountzila, Anna [0000-0002-6801-3129] | |
dc.gnosis.orcid | 0000-0002-2195-9961|0000-0002-6801-3129 | |